#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Solitary fibrous tumour Chronic myelomonocytic leukaemia Subarachnoid haemorrhage Gastrointestinal neuroendocrine tumour Hormone-dependent prostate cancer Neovascular age-related macular degeneration Diffuse large B-cell lymphoma refractory Anti-HLA antibody test positive Eosinophilic oesophagitis Chronic lymphocytic leukaemia refractory White matter lesion Hypocalcaemia Enteritis Deafness Autoimmune haemolytic anaemia More trials…

    Learn about Rare Diseases

    Hepatoblastoma Richter’s syndrome – Life with Disease Advanced systemic mastocytosis – Diagnostics Anaplastic thyroid cancer – Basic Information Angelman’s syndrome – Treatment Paraneoplastic neurological syndrome – Basic Information Factor IX deficiency Choroid melanoma – Life with Disease Ornithine transcarbamoylase deficiency – Life with Disease Mantle cell lymphoma stage II – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Acetylcysteine Dexrazoxane Hydrochloride Oritavancin Olopatadine ZILUCOPLAN Munc-T3 Cladribine Obefazimod AGA2118 CYCLIZINE HYDROCHLORIDE Cobimetinib Lurasidone Lovastatin Amg 193 Sulfur Hexafluoride Namilumab Edotreotide Valaciclovir Agomelatine Inaxaplin More therapies…

    Learn about Your Condition

    Ventricular extrasystoles Strongyloidiasis Factor VIII deficiency Chronic hepatitis C Peritonitis Bipolar I disorder Dementia Cervix carcinoma stage II Cystic fibrosis Persistent depressive disorder Dyskinesia Adenocarcinoma pancreas Hodgkin's disease recurrent Endocarditis enterococcal Proteinuria More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Diagnostic Consultative Centre Ascendent OOD

Diagnostic Consultative Centre Ascendent OOD

Ulitsa Bacho Kiro 47, Sofia, 1202, Bulgaria

Want to learn more about this study or check if you can participate? Contact us.

  • A study comparing cagrilintide and semaglutide combination to semaglutide, cagrilintide, and placebo in adults with type 2 diabetes on metformin

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    Investigated Drugs:
    • Metformin
    • Cagrilintide
    • Dapagliflozin
    Bulgaria Croatia Czechia Denmark Finland Germany +9

  • A study comparing ziltivekimab to placebo in patients with heart failure with mildly reduced or preserved ejection fraction and inflammation

    Not recruiting

    3 1
    Investigated Diseases:
    • Cardiac failure
    Investigated Drugs:
    • Ziltivekimab
    Austria Belgium Bulgaria Croatia Czechia Denmark +18

  • Study on the Effectiveness of an MF59-Adjuvanted Influenza Vaccine Compared to a Non-Adjuvanted Vaccine in Adults Aged 65 and Older

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • A/DARWIN/9/2021 (H3N2) – LIKE STRAIN (A/DARWIN/6/2021, IVR-227)
    • A/Victoria/4897/2022 (H1N1)Pdm09-Like Strain (A/Victoria/4897/2022, Ivr-238)
    • Influenza Virus A/Thailand/8/2022 (H3N2) Ivr-237-Like Strain (A/Thailand/8/2022)
    Belgium Bulgaria Czechia Finland Italy Lithuania +4

  • Study on the Effect of Survodutide on Heart Safety in Patients with Obesity and Cardiovascular or Kidney Disease

    Not recruiting

    3 1
    Investigated Drugs:
    • BI 456906
    • SURVODUTIDE
    Austria Belgium Bulgaria Czechia Denmark Finland +11

  • Study on the Effects of AGA2118 for Postmenopausal Women with Osteoporosis

    Not recruiting

    2 1
    Investigated Drugs:
    • AGA2118
    Bulgaria Denmark Estonia Poland

  • Study on the Effects of Povorcitinib for Patients with Prurigo Nodularis

    Not recruiting

    3 1
    Investigated Diseases:
    • Neurodermatitis
    Investigated Drugs:
    • 4-[3-(Cyanomethyl)-3-(3′,5′-Dimethyl-1H,1’H-[4,4′-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide
    Austria Bulgaria France Germany Italy The Netherlands +1

  • Study of mRNA-1010 Influenza Vaccine Compared to Standard Flu Vaccine in Adults 50 Years and Older

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Cx-037231
    • Cx-039776
    • Cx-044933
    Belgium Bulgaria Estonia Finland Germany

  • Study Comparing MAB-22 and Denosumab for Treating Osteoporosis in Postmenopausal Women

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Osteoporosis
    Investigated Drugs:
    • Denosumab
    Bulgaria Czechia Poland

  • Study on the Effectiveness and Safety of LY06006 and Denosumab for Postmenopausal Women with Osteoporosis

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Denosumab
    Bulgaria Czechia Poland

  • Study on Barzolvolimab for Patients with Chronic Spontaneous Urticaria Unresponsive to H1 Antihistamines

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Barzolvolimab
    • Epinephrine
    Bulgaria Croatia Germany Hungary Italy Lithuania +4
Previous Page
1 2 3 4 5
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!